Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Regarding TMB, more confirmation regarding the higher the value, the higher Response Rate. The JTO aricle states

Average tumor mutational burden (TMB) was low (mean 4.3, range 0-40.3 mutations/Mb). Clinical outcomes to first- and second-generation EGFR TKIs were obtained for 5 patients and none responded.

Here's a section of an article that indicates the higher the TMB, the better the outcomes.

A series of 240 patients with advanced NSCLC profiled by NGS showed that the median tumor mutation burden (TMB) was 7.4 single-nucleotide variants/megabase (Mb). TMB was greater in those who had either partial or stable disease lasting more than 6 months compared with those with no durable benefit following immune checkpoint inhibitor (ICI) therapy (P=0.006), according to Matthew D. Hellmann, MD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues.
A higher rate of progression-free survival (PFS) was also observed in patients with TMB thresholds above -- versus below -- the 50th percentile (38.6% vs 25.1%, P<0.001; hazard ratio 1.38 P=0.024), they reported online in the Journal of Clinical Oncology.
https://www.medpagetoday.com/hematologyoncology/lungcancer/71554?xid=nl_mpt_DHE_2018-03-07&eun=g824783d0r&pos=3&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%202018-03-07&utm_term=Daily%20Headlines%20-%20Active%20User%20-%20180%20days

Regarding JTO noting that

Clinical outcomes to first- and second-generation EGFR TKIs were obtained for 5 patients and none responded.

, pozi seems to be the only game in town right now.